Amgen Splits AMG-706/Avastin Head-To-Head NSCLC Study Into Two Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
One trial will compare the multi-VEGF agent with Avastin in non-squamous non-small cell lung cancer and the second will study AMG-706’s effect in all non-small cell carcinoma patients.
You may also be interested in...
AMG-706 Comparison To Avastin Is Critical To Commercial Success, Amgen Says
Amgen reiterates need to compare the investigational oncologic to Avastin after changing its Phase III clinical program in April.
AMG-706 Comparison To Avastin Is Critical To Commercial Success, Amgen Says
Amgen reiterates need to compare the investigational oncologic to Avastin after changing its Phase III clinical program in April.
Genentech Aims To Extend Avastin Duration Of Use
Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.